Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Empagliflozin38 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A00249 | 35166009 | Diabetes Obes Metab | Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes. | 2022 | Details |
| A00609 | 35030323 | Lancet Gastroenterol Hepatol | Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. | 2022 | Details |
| A00714 | 34992540 | Front Pharmacol | Transcriptomic Analysis Reveals the Protective Effects of Empagliflozin on Lipid Metabolism in Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A00775 | 34971904 | Biochem Biophys Res Commun | Hepatoprotective effects of gemigliptin and empagliflozin in a murine model of diet-induced non-alcoholic fatty liver disease. | 2021 | Details |
| A01378 | 34768942 | Int J Mol Sci | In a Prediabetic Model, Empagliflozin Improves Hepatic Lipid Metabolism Independently of Obesity and before Onset of Hyperglycemia. | 2021 | Details |
| A02192 | 34466320 | Cureus | The Effect of Empagliflozin on Liver Fat in Type 2 Diabetes Mellitus Patients With Non-Alcoholic Fatty Liver Disease. | 2021 | Details |
| A02915 | 34199317 | Int J Mol Sci | Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-Diabetic Obese Biopsy-Proven Mouse Model of Advanced NASH. | 2021 | Details |
| A04359 | 33648515 | Cardiovasc Diabetol | Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study. | 2021 | Details |
| A04362 | 33647823 | Int Immunopharmacol | The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy pathway. | 2021 | Details |
| A04530 | 33586120 | Diabetes Ther | Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. | 2021 | Details |
| A04884 | 33467546 | Int J Mol Sci | Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE(-/-) Mice by Activating Autophagy and Reducing ER Stress and Apoptosis. | 2021 | Details |
| A05042 | 33396949 | Metabolites | Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. | 2020 | Details |
| A05705 | 33148902 | J Med Invest | Long-term empagliflozin therapy improves levels of hepatic fibrosis marker in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus. | 2020 | Details |
| A06190 | 32975679 | Adv Ther | Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. | 2020 | Details |
| A07203 | 32583961 | Clin Transl Sci | Evolving Role for Pharmacotherapy in NAFLD/NASH. | 2020 | Details |
| A08737 | 32006266 | Adv Exp Med Biol | Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors. | 2021 | Details |
| A09583 | 31686884 | Diabetes Metab Syndr Obes | Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician's Guide. | 2019 | Details |
| A09969 | 31540903 | Diabetes Care | Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial. | 2019 | Details |
| A10234 | 31419466 | Mol Cell Endocrinol | Empaglifozin mitigates NAFLD in high-fat-fed mice by alleviating insulin resistance, lipogenesis and ER stress. | 2019 | Details |
| A11204 | 31000862 | J Pak Med Assoc | Expert Opinion: Use of sodium glucose co-transporter type-2 inhibitors in South Asian population -The Pakistan perspective. | 2019 | Details |
| A11911 | 30684076 | Dig Dis Sci | Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus. | 2019 | Details |
| A12365 | 30483596 | JGH Open | Kombiglyze (metformin and saxagliptin)-induced hepatotoxicity in a patient with non-alcoholic fatty liver disease. | 2018 | Details |
| A13245 | 30066148 | Diabetologia | Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial. | 2018 | Details |
| A13582 | 29895557 | Diabetes Care | Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial). | 2018 | Details |
| A14182 | 29547706 | Atherosclerosis | Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors. | 2018 | Details |
| A14510 | 29376471 | Adipocyte | Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: Focus on fat browning and macrophage polarization. | 2018 | Details |
| A17943 | 27462372 | Diabetol Metab Syndr | Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes. | 2016 | Details |
| A29606 | 33808404 | Biomedicines | Dulaglutide Alone and in Combination with Empagliflozin Attenuate Inflammatory Pathways and Microbiome Dysbiosis in a Non-Diabetic Mouse Model of NASH. | 2021 | Details |
| A43800 | 30847693 | Dig Dis Sci | Fat and Fibrosis: Does Empagliflozin Impair the Progression of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus? | 2020 | Details |
| A43883 | 30581509 | Prz Gastroenterol | Empagliflozin promises to bridge the gap between non-alcoholic fatty liver disease, type 2 diabetes, and cardiovascular disease. | 2018 | Details |
| A44116 | 29702499 | Curr Opin Cardiol | New antihyperglycaemic agents and cardiovascular disease: let's be optimistic. | 2018 | Details |
| A44360 | 28845675 | Ann Pharmacother | Acute Hepatitis Caused by Empagliflozin in a Nonalcoholic Fatty Liver Disease Patient. | 2017 | Details |
| A49820 | 35628485 | Int J Mol Sci | Empagliflozin Treatment Attenuates Hepatic Steatosis by Promoting White Adipose Expansion in Obese TallyHo Mice. | 2022 | Details |
| A49867 | 35614469 | Cardiovasc Diabetol | The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management. | 2022 | Details |
| A50741 | 35282455 | Front Endocrinol (Lausanne) | Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. | 2022 | Details |
| A50745 | 35280867 | Front Med (Lausanne) | Efficacy of Off-Label Therapy for Non-alcoholic Fatty Liver Disease in Improving Non-invasive and Invasive Biomarkers: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. | 2022 | Details |
| A51323 | 35624663 | Antioxidants (Basel) | Empagliflozin-Enhanced Antioxidant Defense Attenuates Lipotoxicity and Protects Hepatocytes by Promoting FoxO3a- and Nrf2-Mediated Nuclear Translocation via the CAMKK2/AMPK Pathway. | 2022 | Details |
| A51870 | 33551821 | Front Pharmacol | Empagliflozin Alleviates Hepatic Steatosis by Activating the AMPK-TET2-Autophagy Pathway in vivo and in vitro. | 2021 | Details |